RapidAIM ®
A high-throughput ex vivo microbiome platform to assess drug-microbiome interactions

The RapidAIM technology is a 96-well plate based ex vivo assay that allows the rapid screening of compounds against individual human microbiomes.  RapidAIM greatly accelerates the discovery of compounds that target the human gut microbiome. Our current technology can also be used to de-risk compounds, and to stratify patients based on their personal microbiome responses. 

Using RapidAIM, MedBiome is focusing on the development of compounds that modulate the production of specific metabolites by the human microbiome, specific microbial pathways and enzymes.